anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Little is known about the prevalence of intraspinal pathology in children who toe walk, but magnetic resonance imaging (MRI) may be part of the diagnostic workup. The purpose of this study was to examine the role of MRI for children who toe walk with a focus on the rate of positive findings and associated neurosurgical interventions performed for children with said MRI findings.
METHODS: A single-center tertiary hospital database was queried to identify a cohort of 118 subjects with a diagnosis of toe walking who underwent spinal MRI during a 5-year period. Patient and MRI characteristics were summarized and compared between subjects with a major abnormality, minor abnormality, or no abnormality on MRI using multivariable logistic regression. Major MRI abnormalities included those with a clear spinal etiology, such as fatty filum, tethered cord, syrinx, and Chiari malformation, while minor abnormalities had unclear associations with toe walking.
RESULTS: The most common primary indications for MRI were failure to improve with conservative treatment, severe contracture, and abnormal reflexes. The prevalence of major MRI abnormalities was 25% (30/118), minor MRI abnormalities was 19% (22/118), and normal MRI was 56% (66/118). Patients with delayed onset of toe walking were significantly more likely to have a major abnormality on MRI ( P =0.009). The presence of abnormal reflexes, severe contracture, back pain, bladder incontinence, and failure to improve with conservative treatment were not significantly associated with an increased likelihood of major abnormality on MRI. Twenty-nine (25%) subjects underwent tendon lengthening, and 5 (4%) underwent neurosurgical intervention, the most frequent of which was detethering and sectioning of fatty filum.
CONCLUSIONS: Spinal MRI in patients who toe walk has a high rate of major positive findings, some of which require neurosurgical intervention. The most significant predictor of intraspinal pathology was the late onset of toe walking after the child had initiated walking. MRI of the spine should be considered by pediatric orthopedic surgeons in patients with toe walking who present late with an abnormal clinical course.
LEVEL OF EVIDENCE: Level III Retrospective Comparative Study.
This is a double-blind, pilot study with the goal of testing the effects of tDCS coupled with meditation in the management of visceral pain in patients with chronic pancreatitis. We will enroll a total of 14 subjects with chronic pancreatitis. After enrollment, subjects will be randomized to active stimulation plus mediation (7 subjects) or sham stimulation plus meditation (7 subjects). Subjects will undergo 5 days of active tDCS stimulation plus meditation or sham tDCS plus meditation. Sessions will last approximately 30 min - 1 hour. EEG activity will be measured in the first, last and follow-up visits. After each stimulation session, we will assess for adverse effects using the tDCS adverse effects questionnaire. We will also have the subject fill out a pain/medication diary during the 5 days of treatment. All study procedures will be completed at BIDMC.
BACKGROUND: Obesity is a global epidemic, and the low-grade chronic inflammation of adipose tissue in obese individuals can lead to insulin resistance and type 2 diabetes. Adipose tissue macrophages (ATMs) are the main source of pro-inflammatory cytokines in adipose tissue, making them an important target for therapy. While branched-chain amino acids (BCAA) have been strongly linked to obesity and type 2 diabetes in humans, the relationship between BCAA catabolism and adipose tissue inflammation is unclear. This study aims to investigate whether disrupted BCAA catabolism influences the function of adipose tissue macrophages and the secretion of pro-inflammatory cytokines in adipose tissue, and to determine the underlying mechanism. This research will help us better understand the role of BCAA catabolism in adipose tissue inflammation, obesity, and type 2 diabetes.
METHODS: In vivo, we examined whether the BCAA catabolism in ATMs was altered in high-fat diet-induced obesity mice, and if BCAA supplementation would influence obesity, glucose tolerance, insulin sensitivity, adipose tissue inflammation and ATMs polarization in mice. In vitro, we isolated ATMs from standard chow and high BCAA-fed group mice, using RNA-sequencing to investigate the potential molecular pathway regulated by BCAA accumulation. Finally, we performed targeted gene silence experiment and used immunoblotting assays to verify our findings.
RESULTS: We found that BCAA catabolic enzymes in ATMs were influenced by high-fat diet induced obesity mice, which caused the accumulation of both BCAA and its downstream BCKA. BCAA supplementation will cause obesity and insulin resistance compared to standard chow (STC) group. And high BCAA diet will induce pro-inflammatory cytokines including Interlukin-1beta (IL-1β), Tumor Necrosis Factor alpha (TNF-α) and monocyte chemoattractant protein-1 (MCP-1) secretion in adipose tissue as well as promoting ATMs M1 polarization (pro-inflammatory phenotype). Transcriptomic analysis revealed that a high BCAA diet would activate IFNGR1/JAK1/STAT1 pathway, and IFNGR1 specific silence can abolish the effect of BCAA supplementation-induced inflammation and ATMs M1 polarization.
CONCLUSIONS: The obesity mice model reveals the catabolism of BCAA was disrupted which will cause the accumulation of BCAA, and high-level BCAA will promote ATMs M1 polarization and increase the pro-inflammatory cytokines in adipose tissue which will cause the insulin resistance in further. Therefore, reducing the circulating level of BCAA can be a therapeutic strategy in obesity and insulin resistance patients.
Hyperuricemia is associated with an increased risk of gout, hypertension, diabetes, and cardiovascular diseases. Most mammals maintain normal serum uric acid (SUA) via urate oxidase (Uox), an enzyme that metabolizes poorly-soluble UA to highly-soluble allantoin. In contrast, Uox became a pseudogene in humans and apes over the long course of evolution. Here we demonstrate an atavistic strategy for treating hyperuricemia based on endogenous expression of Uox in hepatocytes mediated by mRNA (mUox) loaded with an ionizable lipid nanoparticle termed iLAND. mUox@iLAND allows effective transfection and protein expression in vitro. A single dose of mUox@iLAND lowers SUA levels for several weeks in two female murine models, including a novel long-lasting model, which is also confirmed by metabolomics analysis. Together with the excellent safety profiles observed in vivo, the proposed mRNA agent demonstrates substantial potential for hyperuricemia therapy and the prevention of associated conditions.
PURPOSE: An anticancer and an adjuvant anticancer composition containing Schizandra chinensis Baillon seed extract are provided to effectively suppress the growth of cancer tissue and angiogenesis. CONSTITUTION: An anticancer and adjuvant anticancer composition contains Schizandra chinensis Baillon seed extract as an active ingredient. The extract is a hexane or methylene chloride organic solvent extract. The extract is water extract. The organic solvent includes methanol, hexane, methylene choride, ethyl acetate, or butanol. The composition is manufactured in the form of a solution, suspension, emulsion, pill, capsule, granule, or tablet.
FIELD: medicine, phytotherapy, geriatrics. SUBSTANCE: the suggested preparation could be applied in treating and preventing catarrhal, inflammatory, allergic diseases, as antitoxic product, etc. It contains herbal decoction or juice, an aqueous-alcoholic solution obtained from licorice root at volumetric portion of ethanol to be 24% and oxygen at the following ratio of components, weight%: herbal decoction or juice 10.0, an aqueousalcoholic solution from licorice root 0.3, oxygen 2000.0- 3000.0. The product in question enables to save biologically active substances of prepared solution by causing no side effects in human body. EFFECT: prolonged terms of storage. 1 cl, 2 ex
FIELD: cosmetology. SUBSTANCE: composition comprises the following ratio of components: resveratrol, 0.5-10%; oxyacid, 0.01-20%; cosmetically acceptable carrier, the balance. Amount of oxyacid can be from 2 to 12 wt.% and pH value can be from 3 to 5. Method for improving or prevention of appearance of wrinkles or dry skin involves application on skin the composition including resveratrol taken in the amount from 0.5 to 10 wt.% and cosmetically acceptable carrier. The aim of invention is the improvement of appearance of wrinkled, dry, rough and senile skin or UV- damaged skin Invention can be used for preparing cosmetic compositions. EFFECT: valuable cosmetic properties of compositions. 4 cl, 11 tbl, 11 ex
This study will describe postoperative pain management for spine surgery patients receiving liposomal bupivacaine (Exparel®) compared to patients not receiving the drug. It is a prospective, randomized clinical trial with two cohorts: Group A: standard of care (SOC) plus liposomal bupivacaine (n=30) and Group B: SOC (n=30). All subjects will undergo open single-level posterior decompression and instrumented fusion for degenerative spondylolisthesis. The surgery is not an experimental procedure. Prior to closing the surgical wound, liposomal bupivacaine will be administered to Group A. The administration of the drug is a study procedure, but note that this is an indicated use of the drug. Postoperatively, subjects will be assessed for pain and opioid consumption. The investigator's hypothesis for statistical analysis is that there will be a 30% decrease in pain medication requirement for the experimental group (Group A: Liposomal bupivacaine ) versus the control group (Group B: No Liposomal bupivacaine).
A gene delivery vector is used to generate genetically modified dendritic cells and B-cells central to the immune system. As a result, genetic modification of cells bearing the CD40 target antigen on its surface can be used to modulate immunity. Previously, both dendritic cells and B-cells have been resistant to gene transfer. The present invention serves to mediate dramatic enhancements in gene transfer to these cell types. Simultaneous with gene transfer, the vector system described herein matures dendritic cells and B-cells to a more potent immunoregulatory status. This invention provides technology for genetic manipulation of dendritic cells and B-cells.
Intestinal ischemia-reperfusion (I/R) injury is a critical condition in the abdomen that has significant morbidity and fatality rates. Prior studies have noted the defensive role of the coenzymatic antioxidant reduced nicotinamide adenine dinucleotide phosphate (NADPH) in heart and brain I/R damage, yet its impact on intestinal I/R trauma required further exploration. Through the application of an in vitro oxygen-glucose deprivation-reoxygenation model and a mouse model of short-term intestinal I/R, this study clarified the defensive mechanisms of NADPH against intestinal I/R injury. We demonstrated that intraperitoneal NADPH administration markedly reduced interleukin-1β (IL-1β) levels and blocked NLRP3 inflammasome activation, hence reducing inflammation. The antioxidative properties of NADPH were established by the reduction of oxidative stress markers and enhancement of glutathione levels. Importantly, NADPH improved intestinal barrier integrity, indicated by an upregulation of zonula occludens-1 and the promotion of a balanced gut microbiome profile. Furthermore, we identified the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1(HO-1) pathway as a crucial conduit for NADPH's beneficence. When this pathway was inhibited by ML385, the favorable outcomes conferred by NADPH were significantly abrogated. These results demonstrate that NADPH functions as an antioxidative, anti-inflammatory, microbiota-balancing, barrier-strengthening, and anti-inflammatory agent against intestinal I/R damage through activation of the Nrf2/HO-1 signaling pathway.
A medicament for treating neurally-transported viral infections, such as herpes simplex, herpes zoster or rabies, comprises a first active substance selected from alkaloids, anaesthetics and griseofulvin and a second active substance comprising a purine analogue or pyrimidine analogue antiviral agent. The alkaloid may comprise colchicine, vinblastine, vincristine, a cytochalasin or their derivatives. Suitable purine analogues include N- substituted guanine derivatives such as aciclovir, valaciclovir, penciclovir, famiciclovir ganciclovir, valganciclovir or pro-drugs that convert thereto in the body, and N-substituted adenine derivatives such as vindarabine. Suitable pyrimidine analogues include thymidine derivatives such as trifluorothymidine. The medicament may be orally administrable, injectable, infusible or topically applicable; a topical medicament may include a local anaesthetic. The medicament may be administered in response to a risk of infection, prior to onset of symptoms. A combination of two preparations may be used, respectively containing the first and second active substances, either administered sequentially or simultaneously.
All patients received topical oral and pharyngeal anesthesia using 2.4% lidocaine spray. The pharyngeal surface was sprayed twice, with each spray lasting one second, and repeated after a 5-minute interval. Ultrasound-guided bilateral Thyroid Cartilage Plane Block is performed using the thyroid cartilage plate as an anatomical landmark. 2.5ml of 2% lidocaine is injected on the surface of the thyroid cartilage each side. Subsequently, perform fiberoptic bronchoscope-guided subglottis and tracheal surface topical anesthesia using 5ml of 2% lidocaine. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
Primary Sjögren Syndrome (pSS) is a chronic autoimmune disease that primarily affects exocrine glands and can lead to various extraglandular manifestations, including secondary immune thrombocytopenia (ITP). Understanding the clinical and hematological differences in pSS patients with and without secondary ITP is crucial for improved patient management and treatment strategies. This retrospective study, conducted from January 2020 to December 2023, involved a cohort of pSS patients, dividing them into 2 groups: those with secondary ITP and those without. Patients were evaluated using the European League Against Rheumatism Sjögren Syndrome Disease Activity Index (ESSDAI), EULAR Sjögren Syndrome Patient-Reported Index (ESSPRI), Health Assessment Questionnaire, and other hematological parameters. Inclusion criteria were based on the American-European Consensus Group or ACR/EULAR classification criteria for pSS. Exclusion criteria included other autoimmune or hematological disorders, prior splenectomy, recent blood transfusions, and lack of informed consent. Statistical analysis was performed using SPSS software, with various tests applied to analyze the data, including logistic regression to identify risk factors for secondary ITP. Significant differences were noted in fatigue, lymphadenopathy, arthritis, mean age, and ESSDAI scores between the secondary ITP and non-secondary ITP groups. Patients with secondary ITP exhibited higher platelet counts, more prevalent lymphopenia, higher immunoglobulin G (IgG) levels, lower complement 3 levels, and reduced white blood cell and hemoglobin levels. Logistic regression analysis identified lymphadenopathy as a risk factor and arthritis as a protective factor for the development of secondary ITP. The study reveals distinct clinical and hematological characteristics in pSS patients with secondary ITP, suggesting a higher disease activity in this subset. These findings underscore the need for further exploration of these associations to develop more precise treatment approaches for pSS, focusing on preventing secondary ITP and improving patient outcomes.
A smart walker system includes a walker attachment and a user proximity sensor. The walker attachment is configured to be attached to the medical assistance walker. The user proximity sensor is in communication with the walker attachment on the medical assistance walker for determining a proximity of the user proximity sensor relative to the walker attachment on the medical assistance walker. The user proximity sensor is configured to be worn by a user. The user proximity sensor is configured to detect when the user moves away from the medical assistance walker a set distance. Wherein, when the user wearing the user proximity sensor moves the set distance away from the walker attachment on the medical assistance walker, the smart walker system is configured to alert the user to use the medical assistance walker.
The present invention provides a method for treating protein tyrosine kinase-mediated conditions by administering to a mammal an agent that increases cell membrane potassium ion conductance. Protein tyrosine kinase-mediated conditions include psoriasis, atherosclerosis and cancers. In one embodiment the agent is a compound that activates endogenous potassium ion channels. In a second embodiment, the agent is a compound which reacts with potassium ion to form a membrane-permeant complex. In a preferred embodiment, the agent is a potassium ion channel protein administered via incorporation of a DNA molecule encoding the protein into the cellular genome. The present invention also includes a pharmaceutical composition comprising a vector containing a gene encoding a potassium ion channel protein in a form suitable for administration to a mammal. In yet another embodiment, the present invention includes a method or assay for determining the activity of compounds which are potential potassium ion channel activators or inactivators. The present invention also comprises a method for determining the virulence of cancerous cells by measuring the potassium ion conductance of the cells.
Methods and compositions to suppress renin expression and blood pressure in mammals are disclosed. Vitamin D and its analogues and derivatives, including Gemini compounds, are negative regulators of renin synthesis and blood pressure. Renin expression and plasma angiotensin II production were increased several fold in vitamin D receptor (VDR) null mice, leading to hypertension, cardiac hypertrophy and increased water intake. Vitamin D or its analogue-mediated regulation of renin expression and blood pressure is independent of calcium metabolism. Vitamin D analogues or derivatives are novel preventive or therapeutic anti-hypertension agents. Assays to identify novel vitamin D analogues or derivatives as anti-hypertensive agents are disclosed.
Carcinogenicity studies have not been performed with romidepsin. Romidepsin was not mutagenic in vitro in the bacterial reverse mutation assay (Ames test) or the mouse lymphoma assay. Romidepsin was not clastogenic in an in vivo rat bone marrow micronucleus assay when tested to the maximum tolerated dose (MTD) of 1 mg/kg in males and 3 mg/kg in females (6 and 18 mg/m2 in males and females, respectively). These doses were up to 1.3-fold the recommended human dose, based on body surface area.

Based on nonclinical findings, male and female fertility may be compromised by treatment with romidepsin. In a 26-week toxicology study, romidepsin administration resulted in testicular degeneration in rats at 0.33 mg/kg/dose (2 mg/m2/dose) following the clinical dosing schedule. This dose resulted in AUC0-∞ values that were approximately 2% the exposure level in patients receiving the recommended dose of 14 mg/m2/dose. A similar effect was seen in mice after 4 weeks of drug administration at higher doses. Seminal vesicle and prostate organ weights were decreased in a separate study in rats after 4 weeks of daily drug administration at 0.1 mg/kg/day (0.6 mg/m2/day), approximately 30% the estimated human daily dose based on body surface area. Romidepsin showed high affinity for binding to estrogen receptors in pharmacology studies. In a 26-week toxicology study in rats, atrophy was seen in the ovary, uterus, vagina and mammary gland of females administered doses as low as 0.1 mg/kg/dose (0.6 mg/m2/dose) following the clinical dosing schedule. This dose resulted in AUC0-∞ values that were 0.3% of those in patients receiving the recommended dose of 14 mg/m2/dose. Maturation arrest of ovarian follicles and decreased weight of ovaries were observed in a separate study in rats after 4 weeks of daily drug administration at 0.1 mg/kg/day (0.6 mg/m2/day). This dose is approximately 30% the estimated human daily dose based on body surface area.
The invention discloses a fresh juice hard capsule for treating acute soft tissue damage. The fresh juice hard capsule comprises a hard capsule shell and fresh juice. Multiple kinds of liquid in the fresh juice are frozen into ice balls at the temperature under -30 DEG C and wrapped in Ooho spherical films. Multiple fresh juice ice balls with the diameters of 0.1-0.5 cm are arranged in the hard capsule shell. The fresh juice is prepared from, by weight, 40-45 parts of scandent schefflera stem and leaf fresh juice, 35-40 parts of oxalis pes-caprae fresh juice and 15-20 parts of brown sugar, and the total part number is 100. Various ice balls in the fresh juice are molten into liquid at the normal temperature. The Ooho spherical films between different kinds of liquid in the fresh juice ensure the stability of the fresh juice and long-term storage of the fresh juice hard capsule. The fresh juice hard capsule has a definite curative effect on acute soft tissue damage and has no obvious toxic or side effect, and the influence of the stability of the compound fresh juice on product quality is avoided.
The invention discloses an oral liquid for coronary heart disease. The oral liquid is prepared from the following raw materials in parts by weight: 228-684 parts of salvia miltiorrhiza, 114-342 parts of red paeony roots, 114-342 parts of ligusticum wallichii, 114-342 parts of red flower, 76-228 parts of lignum dalbergiae odoriferae, 50-150 parts of sucrose and 1-3 parts of sodium benzoate. The preparation method of the oral liquid comprises the following steps: decocting and extracting salvia miltiorrhiza, red paeony root, ligusticum wallichii and lignum dalbergiae odoriferae to obtain an extracted filtrate, warmly extracting red flower to an obtain filtrate, mixing and concentrating the filtrates to obtain a concentrated liquid, uniformly mixing with a boiled and dissolved filtrate of sucrose and sodium benzoate, metering volume, uniformly stirring and filtering to obtain the oral liquid. The oral liquid has effects of promoting qi to activate blood, dispersing blood stasis and promoting blood circulation, is used for treating qi-stagnancy and blood stasis, chest discomfort, cardiodynia, red tongue ecchymosis, stringy pulse, the coronary heart disease, stenocardia and myocardial infarction. The oral liquid is convenient to take, has less pollution and is convenient to carry. The preparation method and the product quality are easy to control.
The present invention relates to bioactive compositions (including, for example, bioactive serum fractions and bioactive extracts) derived from ginseng ( Panax  spp.) fresh whole plant, a particular part of the plant (e.g., rhizome, roots, leaves, stems, flowers, fruit) or any combination of these plant parts. The bioactive serum fractions and bioactive extracts are free of or substantially free of pulegone and/or free of or substantially free of proteins. The present invention also provides products comprising the bioactive serum fractions and/or bioactive extracts. The present invention further provides methods of making and using the bioactive serum fractions and/or bioactive extracts. Further, the bioactive serum fractions and bioactive extracts have anti-inflammatory and/or anti-irritant and/or anti-aging activities.